Y-Mabs Therapeutics Inc YMAB

NAS: YMAB | ISIN: US9842411095   17/05/2024
11,60 USD (-2,11%)
(-2,11%)   17/05/2024

11 maart 2023 · Y-MABS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Y-mAbs To Contact Him Directly To Discuss Their Options · Persbericht

3 maart 2023 · YMAB Investors Have Opportunity to Lead Y-mAbs Therapeutics, Inc. Securities Fraud Lawsuit · Persbericht

22 februari 2023 · Y-MABS THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. - YMAB · Persbericht

17 februari 2023 · YMAB Investors Have Opportunity to Lead Y-mAbs Therapeutics, Inc. Securities Fraud Lawsuit · Persbericht

4 februari 2023 · Y-MABS THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. - YMAB · Persbericht

28 januari 2023 · DEADLINE: Investors in Y-mAbs Therapeutics, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - YMAB · Persbericht

24 januari 2023 · YMAB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of March 20, 2023 in the Class Action Filed on Behalf of Y-mAbs Therapeutics, Inc. Shareholders · Persbericht

23 januari 2023 · Y-MABS INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Y-mAbs To Contact Him Directly To Discuss Their Options · Persbericht

23 januari 2023 · Bronstein, Gewirtz & Grossman, LLC Notifies Y-mAbs Therapeutics, Inc. (YMAB) Investors of Class Action and to Actively Participate · Persbericht

23 januari 2023 · CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Y-mAbs Investors of a Lead Plaintiff Deadline of March 20, 2023 · Persbericht

22 januari 2023 · Y-MABS THERAPEUTICS, INC. (NASDAQ: YMAB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) · Persbericht

22 februari 2021 · Y-mAbs Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares · Persbericht

19 februari 2021 · Y-mAbs to Announce 2020 Financial and Operating Results on February 25, 2021 · Persbericht

18 februari 2021 · Y-mAbs Announces Pricing of Public Offering of Common Stock · Persbericht

16 februari 2021 · Y-mAbs Announces Proposed Public Offering of Common Stock · Persbericht

6 januari 2021 · Y-mAbs Therapeutics to Present At 39th Annual J.P. Morgan Healthcare Conference · Persbericht

Mijn selecties